Literature DB >> 21076614

Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia.

Einar K Rofstad1, Berit Mathiesen.   

Abstract

The development of metastases has been shown to be associated with the microvascular density of the primary tumor in some clinical studies and with the extent of hypoxia in others. The aim of this study was to investigate the validity of these apparently inconsistent observations and to reveal possible links between them. Xenografted tumors of nine melanoma cell lines established from patients with diseases differing in aggressiveness were studied. The aggressiveness of the cell lines was assessed by measuring their lung colonization potential, invasiveness, angiogenic potential, and tumorigenicity. Spontaneous metastasis was assessed in untreated mice and mice treated with neutralizing antibody against vascular endothelial growth factor A (VEGF-A) or interleukin 8 (IL-8). Microvascular density was scored in histologic preparations. Hypoxic fractions were measured by using a radiobiologic assay and a pimonidazole-based immunohistochemical assay. The aggressiveness of the melanoma lines reflected the aggressiveness of the donor patients' tumors. The metastatic propensity was associated with the microvascular density but not with the hypoxic fraction. Anti-VEGF-A and anti-IL-8 treatments resulted in decreased microvascular density and reduced incidence of metastases in all lines. Large hypoxic fractions were not a secondary effect of high cellular aggressiveness, whereas the microvascular density was associated with the cellular aggressiveness. The metastatic propensity was governed by the angiogenic potential of the tumor cells. The differences in microvascular density among the lines were most likely a consequence of differences in the constitutive angiogenic potential rather than differences in hypoxia-induced angiogenesis. VEGF-A and IL-8 may be important therapeutic targets for melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21076614      PMCID: PMC2978911          DOI: 10.1593/neo.10712

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

Review 1.  Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.

Authors:  P B Vermeulen; G Gasparini; S B Fox; C Colpaert; L P Marson; M Gion; J A M Beliën; R M W de Waal; E Van Marck; E Magnani; N Weidner; A L Harris; L Y Dirix
Journal:  Eur J Cancer       Date:  2002-08       Impact factor: 9.162

2.  Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.

Authors:  Einar K Rofstad; Heidi Rasmussen; Kanthi Galappathi; Berit Mathiesen; Kristin Nilsen; Bjørn A Graff
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 3.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

4.  Radiocurability is associated with interstitial fluid pressure in human tumor xenografts.

Authors:  Einar K Rofstad; Jon-Vidar Gaustad; Kjetil G Brurberg; Berit Mathiesen; Kanthi Galappathi; Trude G Simonsen
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

Review 5.  Tumor progression: a brief historical perspective.

Authors:  Peter C Nowell
Journal:  Semin Cancer Biol       Date:  2002-08       Impact factor: 15.707

6.  Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis.

Authors:  Li Zhang; Richard P Hill
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

Review 7.  The hypoxic tumour microenvironment and metastatic progression.

Authors:  Patrick Subarsky; Richard P Hill
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 8.  Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.

Authors:  Johan Bussink; Johannes H A M Kaanders; Albert J van der Kogel
Journal:  Radiother Oncol       Date:  2003-04       Impact factor: 6.280

Review 9.  Cancer genes and the pathways they control.

Authors:  Bert Vogelstein; Kenneth W Kinzler
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

10.  Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8.

Authors:  E K Rofstad; E F Halsør
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  20 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells.

Authors:  Liliana Mendonça; Alexandre Trindade; Catarina Carvalho; Jorge Correia; Marina Badenes; Joana Gigante; António Duarte
Journal:  Clin Exp Metastasis       Date:  2019-05-22       Impact factor: 5.150

3.  Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments.

Authors:  Dianning He; Marta Zamora; Aytekin Oto; Gregory S Karczmar; Xiaobing Fan
Journal:  Phys Med Biol       Date:  2017-09-05       Impact factor: 3.609

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 5.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Authors:  Katrien De Bock; Massimiliano Mazzone; Peter Carmeliet
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

Review 6.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

7.  Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Authors:  Ryan S Turley; Andrew N Fontanella; James C Padussis; Hiroaki Toshimitsu; Yoshihiro Tokuhisa; Eugenia H Cho; Gabi Hanna; Georgia M Beasley; Christina K Augustine; Mark W Dewhirst; Douglas S Tyler
Journal:  Clin Cancer Res       Date:  2012-04-10       Impact factor: 12.531

Review 8.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

9.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

10.  Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.

Authors:  Sarah J Storr; Sabreena Safuan; Angana Mitra; Faye Elliott; Christopher Walker; Mark J Vasko; Bernard Ho; Martin Cook; Rabab A A Mohammed; Poulam M Patel; Ian O Ellis; Julia A Newton-Bishop; Stewart G Martin
Journal:  Mod Pathol       Date:  2011-11-11       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.